Compare DWSN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | CTSO |
|---|---|---|
| Founded | 1952 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 49.7M |
| IPO Year | N/A | N/A |
| Metric | DWSN | CTSO |
|---|---|---|
| Price | $1.96 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 34.8K | ★ 126.1K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $64,312,000.00 | $36,979,520.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $1.08 | $0.60 |
| 52 Week High | $5.54 | $1.61 |
| Indicator | DWSN | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 46.64 |
| Support Level | $1.92 | $0.70 |
| Resistance Level | $2.03 | $0.85 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 48.70 | 52.04 |
Dawson Geophysical Co is a provider of onshore seismic data acquisition services with operations throughout the continental United States and Canada. The company acquires and processes 2 D, 3 D, and multi-component seismic data for clients, ranging from oil and gas companies to independent oil and gas operators for use in the onshore drilling and production of oil and natural gas as well as provides multi-client data libraries. It operates through a single segment being Contract seismic data acquisition and processing services. In addition, the company provides multi-component seismic data surveys which involve the recording of alternative seismic waves. Geographically, it generates maximum revenue from the United States.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.